Dr. Frank Kung of Vivo Capital Shares US Biotech Trends: Weakness Continues After 2021 Peak, Big Pharma Seeks M&A, Intense Oncology & Rare Disease Competition

Dr. Frank Kung, co-founder and executive director of Vivo Capital recently shared the latest biotech trends at the third NBRP Demo Day. He started with the three key elements for start-ups: technology, capital, and talent, and specifically mentioned that biotech investment in the United States has gradually weakened after reaching its peak in 2021 due to various market factors.Despite this, many large pharmaceutical companies have turned to seek M&A targets due to changes in their business models. From August last year to the end of April this year, 5 large-scale M&A deals by companies such as Amgen, Pfizer, and Astellas amounted to a total of $86 billion in purchase price.
 
According to Dr. Frank Kung, funds are the most crucial factor for biotech start-ups. Although technology, funds, and talent are the three key elements widely recognized for business success, insufficient funds will prevent startups from developing talent and successfully commercializing their products, even with excellent technology.
 
Find more news and insights from GlobalBio's: https://lnkd.in/egCs3c_q
#biotech #pharmaceutical #NPRPDemoDay